{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:24:52Z","timestamp":1789604692661,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>One-third of U.S. adults are bothered by excessive sweating and 5% suffer from hyperhidrosis, both of which negatively affect quality-of-life (QoL). A single-use disposable patch using the novel targeted alkali thermolysis (TAT) technology is being developed to address this condition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>Assess the efficacy and safety of the TAT patch for the treatment of excessive sweating using a randomized, double-blind, sham-controlled study design.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Adults with Hyperhidrosis Disease Severity Scale (HDSS) scores of 3 or 4 (<jats:italic toggle=\"yes\">n<\/jats:italic> = 16) were treated with an active or sham patch for up to 3 minutes (as established in a previous unpublished feasibility study) and evaluated weekly for 6 weeks post-treatment. The primary effectiveness measure was improved HDSS at Week-4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The study met its objective. For the primary efficacy measure, 83% of TAT-treated subjects reported HDSS scores of 1 or 2 at Week-4 versus 0% of sham-treated subjects (<jats:italic toggle=\"yes\">p<\/jats:italic> = .0032). Furthermore, 67% of TAT-treated subjects had a 2-point improvement in HDSS scores versus 0% of sham-treated subjects (<jats:italic toggle=\"yes\">p<\/jats:italic> = .0123). Quality-of-life improvement correlated with HDSS. The TAT patch seemed to be well-tolerated; one transient moderate adverse event that resolved without sequelae was reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>The TAT patch successfully demonstrated efficacy and was well-tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003598","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T09:00:11Z","timestamp":1663750811000},"page":"1220-1225","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A Pilot Study of the Safety and Effectiveness of a Novel Device in Subjects With Axillary Hyperhidrosis"],"prefix":"10.1097","volume":"48","author":[{"given":"Joely","family":"Kaufman","sequence":"first","affiliation":[{"name":"Skin Associates of South Florida\/Skin Research Institute, Coral Gables, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy B.","family":"Green","sequence":"additional","affiliation":[{"name":"Skin Associates of South Florida\/Skin Research Institute, Coral Gables, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Cazzaniga","sequence":"additional","affiliation":[{"name":"Skin Associates of South Florida\/Skin Research Institute, Coral Gables, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Canty","sequence":"additional","affiliation":[{"name":"Medical\/Science Communications, TogoRun, New York, New York;"},{"name":"Department of Nutrition, New York University, New York, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Tims","sequence":"additional","affiliation":[{"name":"Candesant Biomedical, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Waugh","sequence":"additional","affiliation":[{"name":"Candesant Biomedical, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/DSS.0000000000000949","article-title":"Prevalence of multifocal primary hyperhidrosis and symptom severity over time: results of a targeted survey","volume":"42","author":"Glaser","year":"2016","journal-title":"Dermatol Surg"},{"issue":"2","key":"R5-20250731","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/09546634.2020.1789541","article-title":"The impact of adolescents' everyday life experiences on their primary hyperhidrosis treatment - a qualitative study","volume":"33","author":"Trettin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21800","article-title":"Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis","volume":"21","author":"Wade","year":"2017","journal-title":"Health Technol Assess"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.det.2014.06.004","article-title":"Impact of hyperhidrosis on quality of life and its assessment","volume":"32","author":"Hamm","year":"2014","journal-title":"Dermatol Clin"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","article-title":"The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2018.11.066","article-title":"The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R10-20250731","first-page":"392","article-title":"Understanding patient experience with hyperhidrosis: a national survey of 1, 985 patients","volume":"17","author":"Glaser","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R11-20250731","first-page":"425","article-title":"Candesant Biomedical, Inc., assignee. Medical devices for generating heat and methods of treatment using same","volume":"11","author":"Waugh","year":"2021","journal-title":"U.S Patent"},{"key":"R12-20250731","first-page":"908","article-title":"A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee","volume":"33","author":"Solish","year":"2007","journal-title":"Dermatol Surg"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","article-title":"Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials","volume":"80","author":"Glaser","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4725.2011.02250.x","article-title":"A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study","volume":"38","author":"Glaser","year":"2012","journal-title":"Dermatol Surg"},{"key":"R19-20250731","first-page":"13","article-title":"Working up a good sweat\u2014the challenges of standardising sweat collection for metabolomics analysis","volume":"38","author":"Hussain","year":"2017","journal-title":"Clin Biochem Rev"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaad.2019.04.015","article-title":"Comparison of patient-reported disease severity and sweat measurements in primary focal hyperhidrosis","volume":"81","author":"Gibbons","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1111\/ijd.12822","article-title":"Distinguishing hyperhidrosis and normal physiological sweat production: new data and review of hyperhidrosis data for 1980-2013","volume":"54","author":"Thorlacius","year":"2015","journal-title":"Int J Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:09:06Z","timestamp":1753999746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003598","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}